Immunocore's hat trick

With three ImmTAC deals completed in a little more than six months, Immunocore Ltd. shouldn't need to sell additional equity anytime soon.

CEO James Noble said the excitement around the cancer immunotherapy space should keep Immunocore busy. "Two years ago we were begging to meet with people, but now we can hardly fit all the meetings in," he said...